Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Recursion Pharmaceuticals, Inc. ( RXRX ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants Christopher Gibson - Co-Founder, CEO & Director Najat Khan - Chief R&D Officer, Chief Commercial Officer and Director Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Good morning. Welcome to the Jefferies London Healthcare Conference.
Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating losses, and significant share dilution, with profitability likely several years away despite strong partnerships and a robust balance sheet. RXRX stock trades at a steep valuation premium, and meaningful revenue from internal drug candidates is not expected until at least 2027.
Recursion Pharmaceuticals, Inc. (RXRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Recursion Pharmaceuticals, Inc. ever had a stock split?
Recursion Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Christopher C. Gibson CEO | NASDAQ (NGS) Exchange | 75629V104 CUSIP |
| US Country | 800 Employees | - Last Dividend | - Last Split | 16 Apr 2021 IPO Date |
Overview
Recursion Pharmaceuticals, Inc. is a pioneering clinical-stage biotechnology firm focused on revolutionizing the drug discovery process by leveraging an integration of technological advancements across various fields including biology, chemistry, automation, data science, and engineering. This innovative approach aims to industrialize and streamline the identification and development of novel therapeutic candidates. Founded in 2013 and based in Salt Lake City, Utah, Recursion Pharmaceuticals has established itself as a leader in utilizing technology to decode complex biological data, thereby accelerating the path from research to treatment. The company's diverse collaborative efforts include partnerships with major entities such as Bayer AG, the University of Utah Research Foundation, Ohio State Innovation Foundation, Roche & Genentech, and Takeda Pharmaceutical Company Limited, further underlining its commitment to advancing healthcare through scientific and technological excellence.
Products and Services
Recursion Pharmaceuticals operates at the forefront of drug discovery for various serious health conditions, advancing a portfolio that spans from clinical trials to preclinical stages. These include:
- REC-994: Currently in Phase 2 clinical trials, this drug candidate is being developed for the treatment of cerebral cavernous malformation, a condition characterized by blood vessel abnormalities in the brain.
- REC-2282: This drug is in Phase 2/3 clinical trials aiming to treat neurofibromatosis type 2, a disorder causing tumors to form on nerve tissue.
- REC-4881: In Phase 1b/2 clinical trial, REC-4881 is targeted to treat familial adenomatous polyposis, a hereditary condition that increases the risk of forming many polyps in the gastrointestinal tract, leading to cancer.
- REC-3964: Undergoing Phase 1 clinical trials, REC-3964 is focused on the treatment of Clostridioides difficile infection, a bacterial infection causing a range of symptoms from diarrhea to life-threatening inflammation of the colon.
- REC-4881 for AXIN1/APC Mutant Cancers: Also, REC-4881 is undergoing a separate Phase 2 clinical trial for the treatment of cancers with AXIN1 or APC mutations, spotlighting the drug's versatility in addressing different conditions.
- RBM39 for HR-Proficient Ovarian Cancer: In the preclinical stage, this product candidate aims to treat HR-proficient ovarian cancer, focusing on a subset of ovarian cancer patients with specific genetic markers.
Contact Information
